This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shelnutt, S. R. Articles by Badger, T. M. Search for Related Content PubMed PubMed Citation Articles by Shelnutt, S. R. Articles by Badger, T. M.

Urinary Pharmacokinetics of the Glucuronide and Sulfate Conjugates of Genistein and Daidzein¹

Arkansas Children’s Nutrition Center, Little Rock, Arkansas 72202

Consumption of soybean-rich diets is thought to provide significant health benefits such as prevention of cancer, primarily because of the high contents of factors such as the isoflavones genistein and daidzein. Isoflavones circulate and are excreted into the urine mainly as glucuronide and sulfate conjugates. This study was conducted to determine the urinary pharmacokinetics of sulfate and glucuronide conjugates of genistein and daidzein. Twelve volunteers consumed a soy beverage providing 1 and 0.6 mg/kg body weight of genistein and daidzein equivalents, respectively. Urine was collected at various times during the 48 h after soy consumption and was digested with either glucuronidase or sulfatase, and the liberated aglycones were extracted and analyzed by liquid chromatography-mass spectrometry. Urinary isoflavone sulfate levels were determined by two methods: (a) assessment of aglycone after sulfatase hydrolysis (measured); or (b) calculated by subtracting the aglycone + glucuronide levels from the total urinary isoflavone levels. The apparent terminal half-life for daidzein sulfate (3.9 ± 0.5 h) that was determined from sulfatase-treated urine was 32% shorter (P 0.02) than that of the calculated daidzein sulfate (5.7 ± 0.08 h). A similar trend was obtained for genistein sulfate (4.5 ± 0.7 versus 6.8 ± 0.1 h). The apparent terminal half-lives for genistein and daidzein glucuronides were 6.0 ± 0.4 and 3.8 ± 0.4 h, respectively. These data suggest that the measured urinary isoflavone sulfate values provide a better understanding of the pharmacokinetics than the calculated values. Additional studies are needed to determine whether the apparent terminal half-lives can be attributed to elimination or absorption processes.

This article has been cited by other articles:

				D Pugazhendhi, K A Watson, S Mills, N Botting, G S Pope, and P D Darbre Effect of sulphation on the oestrogen agonist activity of the phytoestrogens genistein and daidzein in MCF-7 human breast cancer cells J. Endocrinol., June 1, 2008; 197(3): 503 - 515. [Abstract] [Full Text] [PDF]

				C. Manach, G. Williamson, C. Morand, A. Scalbert, and C. Remesy Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies Am. J. Clinical Nutrition, January 1, 2005; 81(1): 230S - 242S. [Abstract] [Full Text] [PDF]

				Z. K. Roughead, J. R. Hunt, L. K. Johnson, T. M. Badger, and G. I. Lykken Controlled Substitution of Soy Protein for Meat Protein: Effects on Calcium Retention, Bone, and Cardiovascular Health Indices in Postmenopausal Women J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 181 - 189. [Abstract] [Full Text] [PDF]

				C. Manach, A. Scalbert, C. Morand, C. Remesy, and L. Jimenez Polyphenols: food sources and bioavailability Am. J. Clinical Nutrition, May 1, 2004; 79(5): 727 - 747. [Abstract] [Full Text] [PDF]

				J. W. Erdman Jr., T. M. Badger, J. W. Lampe, K. D.R. Setchell, and M. Messina Not All Soy Products Are Created Equal: Caution Needed in Interpretation of Research Results J. Nutr., May 1, 2004; 134(5): 1229S - 1233S. [Abstract] [Full Text] [PDF]

				K. D. R. Setchell, N. M. Brown, P. B. Desai, L. Zimmer-Nechimias, B. Wolfe, A. S. Jakate, V. Creutzinger, and J. E. Heubi Bioavailability, Disposition, and Dose-Response Effects of Soy Isoflavones When Consumed by Healthy Women at Physiologically Typical Dietary Intakes J. Nutr., April 1, 2003; 133(4): 1027 - 1035. [Abstract] [Full Text] [PDF]

				J. W. Lampe Isoflavonoid and Lignan Phytoestrogens as Dietary Biomarkers J. Nutr., March 1, 2003; 133(3): 956S - 964. [Abstract] [Full Text] [PDF]

				K. D. Setchell, M. S Faughnan, T. Avades, L. Zimmer-Nechemias, N. M Brown, B. E Wolfe, W. T Brashear, P. Desai, M. F Oldfield, N. P Botting, et al. Comparing the pharmacokinetics of daidzein and genistein with the use of 13C-labeled tracers in premenopausal women Am. J. Clinical Nutrition, February 1, 2003; 77(2): 411 - 419. [Abstract] [Full Text] [PDF]

				Y. Zhang, S. Hendrich, and P. A. Murphy Glucuronides Are the Main Isoflavone Metabolites in Women J. Nutr., February 1, 2003; 133(2): 399 - 404. [Abstract] [Full Text] [PDF]

				S. R Shelnutt, C. O Cimino, P. A Wiggins, M. J. Ronis, and T. M Badger Pharmacokinetics of the glucuronide and sulfate conjugates of genistein and daidzein in men and women after consumption of a soy beverage Am. J. Clinical Nutrition, September 1, 2002; 76(3): 588 - 594. [Abstract] [Full Text] [PDF]

				K. D. Setchell, N. M Brown, L. Zimmer-Nechemias, W. T Brashear, B. E Wolfe, A. S Kirschner, and J. E Heubi Evidence for lack of absorption of soy isoflavone glycosides in humans, supporting the crucial role of intestinal metabolism for bioavailability Am. J. Clinical Nutrition, August 1, 2002; 76(2): 447 - 453. [Abstract] [Full Text] [PDF]

				M. Rivas, R. P. Garay, J. F. Escanero, P. Cia Jr., P. Cia, and J. O. Alda Soy Milk Lowers Blood Pressure in Men and Women with Mild to Moderate Essential Hypertension J. Nutr., July 1, 2002; 132(7): 1900 - 1902. [Abstract] [Full Text] [PDF]

				M. J. Messina and C. L. Loprinzi Soy for Breast Cancer Survivors: A Critical Review of the Literature J. Nutr., November 1, 2001; 131(11): 3095S - 3108. [Abstract] [Full Text] [PDF]